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Use of Cell Proliferation Data in Cancer Risk
Assessment: FDA View
by Robert J. Scheuplein
The possible uses of cell proliferation data in cancer risk assessment can be divided into
three categories: direct use ofmathematical models that incorporate rates of cell proliferation,
use of experimental data on secondary mechanisms produced by cell proliferation, and using
studies of cellular growth rates to extend the dose range of bioassay data. These three
approaches are briefly discussed and some indication of their potential application to cancer
risk assessment is outlined.
Introduction
Ourjob at the Food and Drug Administration (FDA)
is to evaluate the safety of foods, drugs, cosmetics,
devices, and biologics. With respect to the potential
carcinogenesis of any of these regulated products, our
biggest problem by common consent of at least three
Centers, Foods, Drugs, and Veterinary Medicine, is
how to interpret the conventional high-dose rodent
bioassay.
In the foods area, our cancer issues relate either to
a) substances that have been on the market for some
time that turn out to be animal carcinogens on the
basis of newer bioassay data, for example, cyclamate,
saccharin, red no. 3, d-limonene, sugar alcohols, buty-
lated hydroxyanisole (BHA), butylated hydroxytoluene
(BHT), b) carcinogenic contaminants that appear in
foods at low doses, such as polynuclear aromatics
(PNAs), dioxins, furans, polychlorinated biphenyls,
nitrosamines, and aflatoxins, and c) natural carcino-
gens in foods, which we currently accept but which
may in the future turn out to be a far greater issue.
The first category is probably self-limiting, because we
will gradually deal with them, and our statutes on food
additives will not permit approving new substances
with carcinogenic activity. The second and third cate-
gories will probably increase as analytical chemists
find more and more contaminants at lower levels in
food and regulated food products.
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Ourjob is to evaluate the potential human risks in a
credible manner, so they can be rationally controlled.
This means using the relevant scientific information in
a way that will enlist the support of the majority of
expert opinion. We lose credibility in the scientific
community when we fail to consider clear signals or
relevant biological activity like mutation and cell divi-
sion in the interpretation ofcarcinogenicity data.
Current risk assessment procedures were developed
in the days before data on mutation rates and cell pro-
liferation could be obtained. Although in the 1950s and
1960s, there was a general appreciation ofthe role and
importance of mutation and clonal expansion, all one
had in the way of data were tumor incidences at high
doses in rodents. This was a result ofdesign, i.e., stud-
ies in rodents at high doses. In 1979, FDA gathered an
illustrious panel of cancer experts to advise the FDA
on dealing with the burgeoning problem of new pesti-
cides and novel food additives, which seemed to some
to be new and strange chemicals that might be poten-
tially carcinogenic. The panel established the early car-
cinogen testing and evaluation policy for all agencies
established later, such as the Environmental Protection
Agency and the Occupational Safety and Health
Administration.
I believe we never attempted to model cancer risk
quantitatively. What we did was attempt to place an
upper limit on the cancer risk, using an approach and a
series ofassumptions that collectively assured that we
were being conservative. It was primarily a regulatory
exercise, not a scientific one. The fact that you could
take specific features, like the statistical modeling of
the incidence rates and treat them with great sophisti-
cation, while ignoring virtually all of the biological
weaknesses, including the impact of high doses on
metabolism, toxicity, and pharmacokinetics, did notR. J. SCHEUPLEIN
make it more scientific. This leads to the current sub-
ject and the first category of my arbitrary division of
how cell proliferation data might be used in risk
assessment.
Cell Proliferation and Chemical
Carcinogenesis
I divide these possibilities of using cell proliferation
data in carcinogen risk assessment into three cate-
gories: a) direct use ofmathematical models that incor-
porate cell proliferation, b) use ofexperimental data on
secondary mechanisms produced by cell proliferation,
and c) use ofstudies ofcellular growth rates to extend
the dose range ofbioassay data.
Models
Models of the cancer process have been developed
that incorporate cellular proliferation rates as well as
rates of genomic transition. Examples are the MVK
model (1), the Neyman-Scott model (2) and the more
empirical model of Cohen and Ellwein (3). In some-
what different ways, these models allow the possibility
ofincluding chemical-induced stimulation of cell prolif-
eration in a biologically explicit manner. For example,
in an early version of the MVK model (1), an approxi-
mation to the cancer incidence at age tis given by:
I(t)
=goRiJ co(u)exp(BI
-D1)(t
-u)du
There are three important parameters in the model:
the product po0ul, the difference in cell birth and death
rates,B1-DI, and the scale parameter ofthe normal tis-
sue growth curve, CO. The transition rates, k, and go,
are multiplicative factors that affect the overall inci-
dence of the cancer in question, but they do not influ-
ence the shape ofthe incidence curve. The shape ofthe
incidence curve is strongly influenced by the growth
curve of normal tissue at the site of the potential
tumor [CO(u)] and by the cellular kinetics ofthe initial-
ly transformed cells. Cellular proliferation rates enter
the model structure in different ways, depending on
what is assumed about the mechanism of action. The
explicit dependence on the rate ofclonal expansion of
initiated cells occurs through the exponential (B1-D1)
term. If it is also assumed that the chemical causes
toxic damage and induces regenerative hyperplasia to
replace lost cells, then there will be an increase in the
proliferation of normal stem cells, i.e., an increase in
the number ofcells susceptible to transformation. This
mechanism can be factored into the model by allowing
CO(u) to be some function of the birth and death rates
of stem cells, which are themselves taken to be func-
tions ofdose.
The model has implications for the extrapolation of
risks to low-dose exposures. For example, if an agent
affects only the first transition rate, g,u which is
assumed to be a linear function ofdose, then the model
would predict a linear extrapolation of cancer inci-
dence at a given age. However, if clonal expansion
through the (B1-D1) term is assumed to be a linear
function ofdose, then the incidence at a fixed age is far
from a linearfunction ofdose.
It is worth repeating what Moolgavkar and Knudsen
stated in 1981 (1): "Sensible extrapolations can be
made only when the mode of action of the...agent is
known." We can expect that the incidence rates pre-
dicted from these models will eventually become more
credible than estimates from the present default mod-
els because of the inclusion of more biology. We also
expect that the predicted low-dose risks have the
potential of being lower than the predictions of the
default models because of the explicit incorporation of
the potentially dramatic effect of dose on rates ofpro-
liferation of both transformed and normal cells.
Another and more immediate benefit is, and will con-
tinue to be, the ability to formulate and to test various
mechanistic hypotheses about the cancer process.
However, the actual application of these richer bio-
logical models to the direct assessment of human risk
requires a more detailed understanding of the biologi-
cal mechanisms than we now have. It also requires the
detection and measurement of initiated cells and their
size distribution over time. We also need to know more
precisely how the dose ofthe chemical affects the birth
and death rates ofcells.
Given the demands for detailed mechanistic informa-
tion and accurate data measurement ofthe parameters
that these models make, it willbe some time before they
can be used as substitutes for the current default risk
assessment procedures. These newer models are better
than the default models, but in their demand for real
data on specific mechanistic events, they make it clear
how little we really know about cancer risk extrapola-
tion. I think we will be using smaller pieces of the full
mechanistic picture as adjuncts to conventional default
models wellbefore werelytotally onthe newermodels.
Secondary Mechanism
Cellular proliferation is often the underlying mecha-
nism producing detectable and measurable toxicologi-
cal changes in tissue that may be necessary prerequi-
sites to the development of tumors. For example, in
the case of d-limonene, the binding of a2 g-globulin
with the metabolite of the agent results in the block-
age ofthe kidney tubule, necrosis, cell death, and com-
pensating cellular proliferation (5). Ultimately, tumors
arise at these sites in the male rat kidney and they are
believed to be a consequence of the preceding events
(5). A similar scenario probably takes place with sac-
charin. The formation of coarse-surfaced bladder
stones as a consequence offeeding very large doses of
sodium saccharin leads to chronic irritation ofthe blad-
der epithelium, hyperplasia, and eventually tumors (3).
140USE OF CELL PROLIFERATIONDATA IN CANCER RISKASSESSMENT 141
In both cases, there are compelling reasons to believe
that the lesions observed before the onset of the
tumors are both necessary and sufficient to produce
them. At the cellular level, the crucial event appears to
be the onset ofrapid cell proliferation, but in these two
cases, there are also prior, associated lesions that can
be observed independently. These are toxic lesions,
resulting from noncarcinogenic processes and, as such,
may exhibit thresholds. We can establish a safe level for
the substance bythe conventional means ofdetermining
the threshold and applying a suitable safety factor.
Of course, there are also some caveats to consider.
We need evidence that the proposed lesions actually
occur, i.e., the demonstration of preneoplastic kidney
necrosis and the demonstration of bladder stones at
the appropriate tissue sites before the formation ofthe
tumors. We need evidence that the proposed mecha-
nism is biologically plausible. We need evidence that
the tumors are not also being produced by some inde-
pendent mechanism. As a specific example of the lat-
ter, we would want evidence that the substance or its
metabolites are not mutagenic.
This seems to be a promising approach for the near
term because it, in essence, relies on our ability to
identify crucial toxicological events prerequisite to cer-
tain cancers without having to explain them at the
molecular level. For these cases, we reduce the cancer
risk assessment problem to one we already know how
to solve, that oforgan-specific toxicity.
In some instances, we may be unable to find a lesion
associated with abnormal proliferation. For example,
high levels ofdietary sodium chloride can increase sus-
ceptibility to chemically induced gastric cancer, presum-
ablythrough the regenerative hyperplasiainduced in an
effort to replace the cells necrotized by the salt. The
only visible lesion is the hyperplasia itself. Similarly,
BHA produces tumors only in the forestomach of
rodents and the only prior lesion is the hyperplasia
itself. The rapid onset ofthe hyperplasia, its dependence
on high dose, its reversibility on removing the agent,
and the plausibility of the mechanism on theoretical
grounds all support the idea that the induced abnormal
cellular growth is the cause ofthe cancer. But the case
is more difficult to prove because regenerative hyper-
plasia alone does not always lead to cancer.
Direct Use ofCell Proliferation Rates
When we cannot identify a secondary mechanism,
there still may be the possibility of augmenting the
statistical power ofthe bioassay by using cell prolifera-
tion rates directly. If we believe that cell proliferation
rates increase during the process offormation of some
tumors, then the dose response of the tumors and the
-accompanying cell proliferation should be relatable. If
we measure the rate at which cell proliferation increas-
es with dose, it should reflect and perhaps predict
tumor growth. But the particular cells that need to be
measured need to be reliably identified, as there still is
controversy over the capability of current enzyme
markers to detect "initiated cells" (5).
We may be able to more reliably measure cell prolif-
eration than tumor formation for several reasons.
First, the number ofcells available for observation and
measurement will surely exceed the number ofanimals
typical of the carcinogen bioassay and will give the
observations more statistical power. Second, we may
be able to apply more technical sophistication to the
measurement of cell growth and identify the process
earlier and at lower doses. Such techniques may allow
us to extend the dose-response curve downward an
order of magnitude or so, and from that point on we
could apply our linear default with less error.
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